Stimulation of in Vivo Angiogenesis Using Dual Growth Factor-loaded Crosslinked Glycosaminoglycan Hydrogels.
From: Department of Chemical Engineering, Oregon State University, 103 Gleeson Hall, Corvallis, OR 97331, USA.
Biomaterials
- Publish Date: Dec 2006
- ISSN: 0142-9612
- Volume: 27
- Issue: 35
- Pages: 5935-43
- Medium: Print
- Language: English
- Citation (JAMA): Riley Celeste M, Fuegy Peter W, Firpo Matthew A, et al. Stimulation of in Vivo Angiogenesis Using Dual Growth Factor-loaded Crosslinked Glycosaminoglycan Hydrogels.. Biomaterials Dec 2006;27:5935-43
Abstract
Crosslinked, chemically modified hyaluronan (HA) hydrogels pre-loaded with two cytokine growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), were employed to elicit new microvessel growth in vivo, in both the presence and absence of heparin (Hp) in the gels. HA hydrogel film samples were surgically implanted in the ear pinnae of mice, and the ears were harvested at 7 or 14 days post-implantation. Analysis of neovascularization showed that each of the treatment groups receiving an implant, except for HA/Hp at day 14, demonstrated significantly more microvessel density than control ears undergoing surgery but receiving no implant (p<0.015). Treatment groups receiving either Ang-1 alone, or aqueous co-delivery of both Ang-1 and VEGF, were statistically unchanged with time. In contrast, film delivery of both growth factors produced continuing increases in vascularization from day 7 to day 14 in the absence of Hp, but decreases in its presence. However, presentation of both VEGF and Ang-1 in crosslinked HA gels containing Hp generated intact microvessel beds with well-defined borders. The HA hydrogels containing Ang-1+VEGF produced the greatest angiogenic response of any treatment group tested at day 14 (NI=7.44 in the absence of Hp and 4.67 in its presence, where NI is a neovascularization index). Even in the presence of Hp, this had 29% greater vessel density than the next largest treatment group receiving HA/Hp+VEGF (NI=3.61, p=0.04). New therapeutic approaches for numerous pathologies could be notably enhanced by the localized, sustained angiogenic response produced by release of both VEGF and Ang-1 from crosslinked HA films.
Mesh Headings (Keywords): Angiopoietin-1, Animals, Glycosaminoglycans, Hydrogels, Male, Mice, Mice, Inbred BALB C, Neovascularization, Physiologic, Vascular Endothelial Growth Factor A
Check for Full Text / PubMed Unique Identifier (PMID): 16950508
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.